Market Overview

NeoStem's Progenitor Cell Therapy Enters Deal for Cell Therapy Manufacturing Services

Related NBS
Valeant CEO Addresses Investor Concerns In Letter; Will It Help The Stock Price?
Stocks Hitting 52-Week Lows

NeoStem, Inc. (NYSE: NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1^c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see, identifiers NCT01350401, NCT01343043 and NCT01352286).

Posted-In: News Contracts


Related Articles (NBS)

View Comments and Join the Discussion!